Clindata^® Article 11 for Specialization, fine, characteristic, novel

1. China's first innovative CRO focusing on innovative strategies and design of innovative drugs for major diseases such as cancer

2. China's first clinical CRO protected by intellectual property rights

3. The first clinical CRO in China that adopts "5 ONE +3 major reports +1 PD"

4. The first clinical CRO designed by BOIN in China

5. The first clinical CRO using BOIN+BOP II design in China

6. Mr. Guo Dongsheng, founder of Clindata^®, is the first person to adopt BOIN design for innovative drugs in China

7. Clinical CRO designed by BOIN is the most frequently used by Local innovative drugs in China

8. China's first clinical CRO with proprietary intellectual property rights in the strategy, design, execution, analysis, reporting and interpretation of bridging clinical trials

9. The first clinical CRO in China to join the brand library of Chinese enterprises

10. The first clinical CRO in China to reach strategic cooperation with CCTV "Great Power Ingenuity"

11. Clindata^® is the first clinical CRO of the Drug Regulatory Regulation and Policy Research Committee of China Medical Products Regulatory Society